Antiretroviral Therapy in Latin America: North of the Southern Cone, a Good Plan Is Hard to Find By Richard Stern Seguro Social or Bust When Agua Buena's Richard Stern writes, below, about a recent trip to the AIDS hospitals and…
By Richard Stern At this point I would like to present some examples of a few "best case" scenarios of access to antiretroviral access in the region. This is by no means a complete list. Agua Buena participated in the…
Latest Licensure Breaks Records for Ho-Hum Reception, yet What Exactly Is There to Be Excited About? By Rob Camp A Co-Formulation Elation? Separated at Birth 3TC Emtriva Earlier this month, the fluoronated 3TC agent, FTC (emtricitabine, Emtriva) received FDA approval…
Take-No-Prisoners Tack on TAG Pipeline Report Snubs Host of Drab Wannabes; Cozies up to Fevered Few "Burned One Time Too Many" Someone's been reading too many Dow Jones publications this summer. For what began as a kind of no-nonsense clinical…
Debating the Relevance of Super SIVs— Plus Dendritic Cells Make Their Big Screen Debut By Richard Jeffreys HIV, in flagrante delicto With part two of our review of the immunological and vaccine offerings at this year’s Retrovirus conference, Richard Jefferys…
Activist Coalition’s Cries Threaten To Scuttle BMS’ Race To Full Approval For Wily Reyataz Getting the labeling wrong On May 13 an FDA advisory committee gave backing to the full approval of Bristol-Myers Squibb’s new protease inhibitor, atazanavir (Reyataz). The…
By Richard Jeffreys The field of immune-based therapies (IBT) offers hope that researchers can develop strategies allowing people with HIV to delay or interrupt antiretroviral therapy, ideally reducing drug resistance problems and side effects due to HAART (highly active antiretroviral…
Acute Rx Paradigm Dealt Heavy Blow, While Neutralizing Antibodies Stage a Comeback By Richard Jefferys Remune to the Rescue? The immunological offerings at this year's Retrovirus conference seemed full of challenges to the conventional wisdom -- just the sort of…
Can a Conference (and an Activist) Outlive Its Utility? A Moment of Unabashed Navel Gazing By David Barr Life Without AIDS, Nearly ACT UP/Paris founder Didier Lestrade put away his Doc Marten black high-top boots back in the Mitterand years…
January: HIV vaccine papers in Nature by Merck's Emilio Emini, Harvard's Dan Barouch. February: First ATAC (AIDS Treatment Activist Conference) teach-in, Seattle (seventy people attend), followed by ATAC/BMS meeting and Retrovirus conference. NIH cancels large phase III canarypox HIV vaccine…